MTOR and acute myeloid leukemia: In pediatric AML, the transmembrane receptor CD69 was found to be highly expressed in chemoresistant hematopoietic stem cell (HSC)-like populations, which were termed the “CD69+ HSC-like subpopulation”, manifesting suppression of the mTOR signaling pathway and promotion of cell quiescence and adhesion [69].